Article Text

Download PDFPDF
Response to editorial on subcutaneous diuretics
  1. Duwarakan Satchithananda1,
  2. Angela Ingram2 and
  3. Claire Hookey3
  1. 1Department of Cardiology, University Hospital of North Staffordshire, Stoke-on-Trent, UK
  2. 2Staffordshire and Stoke-on-Trent Partnership NHS Trust, Stoke-on-Trent, UK
  3. 3Douglas Macmillan Hospice, Stoke-on-Trent, UK
  1. Correspondence to Dr Duwarakan Satchithananda, University Hospital of North Staffordshire, Cardiology, Stoke-on-Trent st4 6qg, UK; dargoi.satchi{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the editorial concerning the use of subcutaneous furosemide in heart failure. We feel that there is substantial opportunity for misinterpretation of the editorial by readers not as familiar with the issues raised as the eminent authors themselves.

This particularly relates to:

Heart failure syndrome

It is important to emphasise that the editorial relates to the treatment of congestive symptoms in patients with the heart failure syndrome irrespective of its causal mechanism, that is, left ventricular systolic dysfunction is only one of the many mechanisms inducing this syndrome. This means that 50% of patients hospitalised with heart failure do not have left ventricular systolic dysfunction.1 2

The use of furosemide in heart failure symptom relief

It is important to recognise that the lack of evidence suggested for subcutaneous furosemide is equally applicable to any route of delivery for …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.